Literature DB >> 16054473

Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus > or =70 years of age.

Gabe B Bleeker1, Martin J Schalij, Sander G Molhoek, Eric Boersma, Paul Steendijk, Ernst E van der Wall, Jeroen J Bax.   

Abstract

In the present study, the effects of cardiac resynchronization therapy (CRT) in elderly patients were evaluated. The study included 170 consecutive patients whose clinical and echocardiographic improvements were evaluated after 6 months of follow-up. Survival was evaluated up to 2 years. The effects of CRT in elderly patients (age > or =70 years) were compared with those in younger patients (age <70 years).

Entities:  

Mesh:

Year:  2005        PMID: 16054473     DOI: 10.1016/j.amjcard.2005.03.091

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Cardiac resynchronization therapy is effective even in elderly patients with comorbidities.

Authors:  Natália António; Carolina Lourenço; Rogério Teixeira; Fátima Saraiva; Lourenço Coelho; Miguel Ventura; João Cristóvão; Luís Elvas; Lino Gonçalves; Luís A Providência
Journal:  J Interv Card Electrophysiol       Date:  2009-11-25       Impact factor: 1.900

2.  Comparison of pharmacological treatment alone versus treatment combined with cardiac resynchronization therapy in patients over 75 years.

Authors:  Elena de la Cruz; Marcelino Cortés; Jerónimo Farré; Julia Palfy; Paloma Ávila; Ignacio Hernández; Angélica Romero; Juan Benezet; Juan Antonio Franco; Miguel Angel Navas; Jose Joel Hernandez; Sem Briongos; José M Rubio
Journal:  J Interv Card Electrophysiol       Date:  2015-02-17       Impact factor: 1.900

Review 3.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

4.  Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.

Authors:  Celestino Sardu; Raffaele Marfella; Gaetano Santulli
Journal:  J Cardiovasc Transl Res       Date:  2014-02-06       Impact factor: 4.132

Review 5.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

6.  Relationship between left ventricular dyssynchrony and reverse remodeling after cardiac resynchronization therapy.

Authors:  Umut Celikyurt; Ahmet Vural; Tayfun Sahin; Teoman Kilic; Aysen Agacdiken; Dilek Ural
Journal:  Clin Cardiol       Date:  2011-09-12       Impact factor: 2.882

Review 7.  Resynchronization: considering device-based cardiac therapy in older adults.

Authors:  Daniel B Kramer; Matthew R Reynolds; Susan L Mitchell
Journal:  J Am Geriatr Soc       Date:  2013-03-21       Impact factor: 5.562

8.  Benefit of cardiac resynchronization in elderly patients: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.

Authors:  Jordana Kron; Juan M Aranda; William M Miles; Thomas A Burkart; Gregory W Woo; Sherry J Saxonhouse; Samuel F Sears; Jamie B Conti
Journal:  J Interv Card Electrophysiol       Date:  2009-01-19       Impact factor: 1.900

9.  Effects of cardiac resynchronization therapy on health-related quality of life in older adults with heart failure.

Authors:  Karin F Hoth; Justin Nash; Athena Poppas; Kristin E Ellison; Robert H Paul; Ronald A Cohen
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

Review 10.  Imaging techniques in cardiac resynchronization therapy.

Authors:  Maria Isabel Sá; Albert de Roos; Jos J M Westenberg; Lucia J M Kroft
Journal:  Int J Cardiovasc Imaging       Date:  2007-05-15       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.